pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,002 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1857Endpoints1442Fierce Biotech761BioSpace748BioPharma Dive544raps249onclive165fda recalls118
therapy area
allOncology12851Rare Disease3326Immunology2995Cardiology2845Hematology2286Pulmonology2244Vaccines
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 1d agoCRLNegative↗ source
  • Flagship invests £100 million to launch AI-native biotech platform hub in the United Kingdom
    Flagship announced it will allocate £100 million to establish a new biotech creation outpost in the United Kingdom. The outpost will focus on building AI-native platform companies that aim to addr…
    STAT · 21h agoDealPositive
← prev
page 2 of 121
next →
fda medwatch114
globenewswire health73
fda press61
1852
Psychiatry & CNS1229
Ophthalmology1131
Endocrinology & Metabolism806
Pain790
Nephrology783
↗ source
  • Flavored nicotine tablets launch, raising concerns over appeal to youth
    New flavored nicotine tablets that melt in the mouth have been introduced by tobacco companies in several markets. Products include Zyn Melts by Philip Morris International in the United Kingdom…
    STAT · 1d agoNegative↗ source
  • U.S. loses measles elimination status, sparking political criticism of vaccination response
    International health officials from the Pan American Health Organization announced that measles is no longer considered eliminated in the United States. The designation, first achieved in 2000, is…
    STAT · 22h agoRegulatoryNegative↗ source
  • Larbi Inc. recalls three lots of Yellow Dock Root over possible Salmonella contamination
    Larbi Inc. announced a recall of three lots of its Herb To Body Yellow Dock Root 4-oz product because it may be contaminated with Salmonella. The product was sold nationwide from January to Novemb…
    fda recalls · 15h agoCRLNegative↗ source
  • Democrats rally behind Medicare for More as Trump's chief of staff backs the plan
    Democrats are increasingly uniting around a new health care proposal called Medicare for More, which aims to broaden coverage beyond the existing system. The plan is drawing attention after the Wh…
    STAT · 23h agoNeutral↗ source
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 1d agoNeutral↗ source
  • Biotech boards see more women, but CEO roles remain largely male-dominated
    Women now occupy roughly 29% of biotech board seats, a notable rise from about one‑fifth a few years ago, according to the latest Bedford Group Transearch report. Despite that progress, female CEO…
    BioSpace · 1d agoNegative↗ source
  • CMS releases new AI roadmap; highlights from HLTH conference
    The latest STAT Health Tech newsletter reports that the Centers for Medicare & Medicaid Services (CMS) has published a new artificial intelligence (AI) roadmap outlining its approach to AI integrat…
    STAT · 21h agoRegulatoryNeutral↗ source
  • RFK Jr. urges federal funding for faith-based addiction recovery centers, sparking expert concerns over medication access
    Health Secretary Robert F. Kennedy Jr. toured Sheepgate, a Christian addiction recovery center in Iowa, and said the model should receive federal funding. He highlighted the center as an example of…
    STAT · 1d agoRegulatoryNeutral↗ source
  • Zero-tolerance signs in hospitals may not curb staff violence, authors argue
    Hospitals across the United States now display signs telling patients and visitors that abusive language, disruptive conduct, or aggression will not be tolerated and may result in removal or police…
    STAT · 1d agoNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 23h agoLayoffsNegative↗ source
  • Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
    A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
    BioSpace · 1d ago↗ source
  • IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costs
    IQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
    BioSpace · 2d agoNegative↗ source
  • FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutation
    The U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
    STAT · 1d agoApprovalPositive↗ source
  • Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trial
    Novo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emerge
    Helus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…
    BioSpace · 1d agoNegative readoutNegative↗ source
  • J&J buys Ollin Biosciences for $2.2 billion, taps Blackstone for $750 million Phase 3 eye drug funding
    Johnson & Johnson announced it will acquire Texas‑based ophthalmology biotech Ollin Biosciences, paying $2.2 billion upfront for the company and its late‑stage bispecific antibody targeting retinal…
    BioSpace · 1d agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assets
    Eli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…
    BioSpace · 1d agoDealPositive↗ source
  • FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival data
    The FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…
    BioSpace · 1d agoCRLNegative↗ source
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 2d agoPositive readoutPositive↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi for redosable DNA medicines
    Seawolf Therapeutics announced a $100 million Series A financing backed by investors including Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics and others. The company also disclosed a multi‑…
    BioSpace · 2d agoDealPositive↗ source
  • Trump administration proposes new Medicare Advantage audit rule aiming to curb fraud and save $90 billion
    The Trump administration on Monday proposed new regulations that would reissue Biden-era rules and focus on more aggressive audits of Medicare Advantage plans to combat fraud. Officials say the ru…
    STAT · 1d agoRegulatoryNeutral↗ source
  • Expert warns that newer obesity GLP-1 drugs could spark access battles in low-income nations
    Lower‑cost generic versions of semaglutide, sold as Wegovy for obesity, have begun appearing in several markets and are expected to reach more countries soon. At the same time, pharmaceutical compa…
    STAT · 1d agoNegative↗ source
  • Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surge
    Biotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…
    STAT · 1d agoDealNeutral↗ source